Risk of Myocarditis after Covid-19 mRNA Vaccination: Impact of Booster Dose and Dosing Interval
View ORCID ProfileStéphane Le Vu, View ORCID ProfileMarion Bertrand, View ORCID ProfileMarie-Joëlle Jabagi, View ORCID ProfileJérémie Botton, View ORCID ProfileAlain Weill, View ORCID ProfileRosemary Dray-Spira, View ORCID ProfileMahmoud Zureik
doi: https://doi.org/10.1101/2022.07.31.22278064
Stéphane Le Vu
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Marion Bertrand
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Marie-Joëlle Jabagi
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Jérémie Botton
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
2Faculté de Pharmacie, Université Paris-Saclay, 92296, Châtenay-Malabry, France
Alain Weill
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Rosemary Dray-Spira
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Mahmoud Zureik
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
3University Paris-Saclay, UVSQ, University Paris-Sud, Inserm, Anti-infective evasion and pharmacoepidemiology, CESP, Montigny le Bretonneux, France
Article usage
Posted August 01, 2022.
Risk of Myocarditis after Covid-19 mRNA Vaccination: Impact of Booster Dose and Dosing Interval
Stéphane Le Vu, Marion Bertrand, Marie-Joëlle Jabagi, Jérémie Botton, Alain Weill, Rosemary Dray-Spira, Mahmoud Zureik
medRxiv 2022.07.31.22278064; doi: https://doi.org/10.1101/2022.07.31.22278064
Subject Area
Subject Areas
- Addiction Medicine (322)
- Allergy and Immunology (625)
- Anesthesia (162)
- Cardiovascular Medicine (2339)
- Dermatology (205)
- Emergency Medicine (374)
- Epidemiology (11707)
- Forensic Medicine (10)
- Gastroenterology (693)
- Genetic and Genomic Medicine (3691)
- Geriatric Medicine (347)
- Health Economics (632)
- Health Informatics (2371)
- Health Policy (927)
- Hematology (340)
- HIV/AIDS (773)
- Medical Education (364)
- Medical Ethics (104)
- Nephrology (396)
- Neurology (3456)
- Nursing (195)
- Nutrition (520)
- Oncology (1804)
- Ophthalmology (533)
- Orthopedics (218)
- Otolaryngology (286)
- Pain Medicine (231)
- Palliative Medicine (66)
- Pathology (444)
- Pediatrics (1021)
- Primary Care Research (415)
- Public and Global Health (6093)
- Radiology and Imaging (1260)
- Respiratory Medicine (821)
- Rheumatology (375)
- Sports Medicine (320)
- Surgery (397)
- Toxicology (50)
- Transplantation (171)
- Urology (145)